Liver-Specific Factor VIII Expression Constructs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for treating hemophilia A face challenges in achieving high-level expression of therapeutic proteins in liver cells and inducing tolerance to these proteins, particularly due to the formation of inhibitory antibodies against factor VIII or IX proteins and their delivery vehicles.
Innovation Solution
The development of polynucleotide expression constructs with liver-specific enhancer sequences, promoters, and intron sequences, integrated into the genome via nuclease-mediated targeted integration, which drive high-level expression of proteins like factor VIII in liver cells, combined with strategies to induce tolerance to these proteins through immunomodulatory treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional gene therapy vectors are used to deliver transgenes to liver cells, then gene delivery is achieved, but therapeutic protein expression levels are insufficient
Solution Approach 1:
The patent modifies key parameters of the expression construct including using enhanced liver-specific promoters (e.g., albumin, APOE), adding multiple enhancer elements (e.g., C/EBP, HNF-1 binding sites), and optimizing intron sequences to dramatically increase transcriptional activity and protein expression levels in hepatocytes
Solution Approach 2:
The expression construct is designed as a composite genetic element combining multiple functional components: promoter regions, enhancer sequences, intron sequences with splice sites, and polyadenylation signals, all optimized to work synergistically to achieve high-level sustained expression
2Productivity
If transgenes are expressed at high levels in liver cells, then therapeutic benefit is improved, but inhibitory antibody formation increases
Solution Approach 1:
The patent introduces immunomodulatory agents as intermediaries that mediate between the transgene expression system and the host immune system. These agents (e.g., rapamycin, cyclosporine A, sirolimus) suppress T-cell activation and antibody formation, allowing high-level protein expression without triggering inhibitory immune responses
Solution Approach 2:
Immunosuppressive treatments are administered before or concurrent with transgene delivery to preemptively suppress the immune system's ability to form inhibitory antibodies, preventing the harmful immune response before it can develop
3Reliability
If replacement therapy is administered frequently to maintain therapeutic protein levels, then hemophilia symptoms are controlled, but treatment complexity and cost increase
Solution Approach 1:
The patent achieves more than sufficient therapeutic protein levels through high-level transgene expression, creating a durable therapeutic effect that eliminates or dramatically reduces the need for repeated replacement therapy administrations
Solution Approach 2:
The gene therapy approach enables the patient's own liver cells to continuously produce the therapeutic protein autonomously, eliminating dependence on external repeated administrations of replacement therapy
Data Source
AI summary
Described herein are constructs used for liver-specific expression of a transgene.